Skip to content
pharmaceutical hero image
pharmaceutical hero image


We act for many of the world’s largest pharmaceutical companies, giving us broad and deep insights into the key trends and risks facing companies operating in the sector.

We advise on a wide range of complex cases, working with both national and international clients on high-profile and strategic matters. We have gathered significant and relevant experience of acting for leading companies in the life sciences sector on regulatory issues and we have built a track record of running a number of multi-jurisdictional matters. We also have a strong offering advising pharmaceuticals on transactions including M&A, collaborations and fundraising.

News and insights

Lab microscope

Blog Post: 22 September 2023

Podcast: The regulatory interplay between medical devices and medicines in clinical trials - EU and U.S. focus (Part 1)

The regulatory frameworks for medicines and medical devices have historically grown up on separate tracks, but increasingly, medicines and medical devices are being used together in patients as drug…

Read more
Healthcare worker in mask and goggles

Blog Post: 06 September 2023

Podcast: The European Commission’s proposal for EU pharmaceutical legislation - a deep dive by our life sciences experts

The European Commission published the long awaited proposals for major revision of pharmaceutical law in the European Union.

Read more
Person wearing protective clothing and holding apparatus in science lab

Blog Post: 30 August 2023

Webinar: Managing supply chain risk in the life sciences sector

In increasingly complex and uncertain economic times, companies in the life sciences sector are facing unique supply chain challenges.

Read more
Heap of medical pills in white, blue and other colors. Pills in plastic package. Concept of healthcare and medicine.

Blog Post: 29 August 2023

HHS selects the first drugs for Medicare drug price negotiation

On August 29, 2023, Health and Human Services (“HHS”) announced the first ten drugs covered by Medicare Part D selected for negotiation under President Biden’s Inflation Reduction Act of 2022 (“IRA”),…

Read more